Department of Surgery, Franciscus Gasthuis & Vlietland, Kleiweg 500, 3045, PM, Rotterdam, The Netherlands.
Department of Statistics and Education, Franciscus Academy, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.
Obes Surg. 2020 Feb;30(2):553-559. doi: 10.1007/s11695-019-04188-6.
Morbid obesity is an important risk factor for developing a venous thromboembolic events (VTE) after surgery. Fast-track protocols in metabolic surgery can lower the risk of VTE in the postoperative period by reducing the immobilization period. Administration of thromboprophylaxis can be a burden for patients. This study aims to compare extended to restricted thromboprophylaxis with low molecular weight heparin (LMWH) for patients undergoing metabolic surgery.
In this single center retrospective cohort study, data was collected from patients undergoing a primary Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) between 2014 and 2018. Patients operated in 2014-2017 received thromboprophylaxis for two weeks. In 2018, patients only received thromboprophylaxis during hospital admission. Patients already using anticoagulants were analyzed as a separate subgroup. The primary outcome measure was the rate of clinically significant VTEs within three months. Secondary outcome measures were postoperative hemorrhage and reoperations for hemorrhage.
3666 Patients underwent a primary RYGB or SG following the fast-track protocol. In total, two patients in the 2014-2017 cohort were diagnosed with VTE versus zero patients in the 2018 cohort. In the historic group, 34/2599 (1.3%) hemorrhages occurred and in the recent cohort 8/720 (1.1%). Postoperative hemorrhage rates did not differ between the two cohorts (multivariable analysis, p = 0.475). In the subgroup of patients using anticoagulants, 21/347(6.1%) patients developed a postoperative hemorrhage. Anticoagulant use was a significant predictor of postoperative hemorrhage (p < 0.001).
Despite the restricted use of thromboprophylaxis administration since 2018, the rate of VTEs did not increase. This may be explained by quick mobilization and hospital discharge, as encouraged by the fast-track protocol. There was no significant difference in postoperative hemorrhage rates by thromboprophylaxis protocol. Short term use of thromboprophylaxis in metabolic surgery is safe in patients at low risk of VTE.
病态肥胖是手术后发生静脉血栓栓塞事件(VTE)的重要危险因素。代谢手术中的快速通道方案可以通过减少固定期来降低术后 VTE 的风险。给予血栓预防治疗可能会给患者带来负担。本研究旨在比较低分子肝素(LMWH)延长至限制血栓预防治疗在代谢手术患者中的效果。
在这项单中心回顾性队列研究中,收集了 2014 年至 2018 年间接受原发性 Roux-en-Y 胃旁路术(RYGB)或袖状胃切除术(SG)的患者的数据。2014-2017 年接受手术的患者接受了两周的血栓预防治疗。2018 年,仅在住院期间对患者进行血栓预防治疗。已经使用抗凝剂的患者被作为单独的亚组进行分析。主要结局指标是三个月内临床显著 VTE 的发生率。次要结局指标是术后出血和再次手术治疗出血。
3666 例患者接受了快速通道方案的原发性 RYGB 或 SG。在 2014-2017 年队列中,共有 2 例患者被诊断为 VTE,而 2018 年队列中无患者被诊断为 VTE。在历史组中,2599 例中有 34 例(1.3%)发生了术后出血,而在最近的队列中,720 例中有 8 例(1.1%)。两组的术后出血率无差异(多变量分析,p=0.475)。在使用抗凝剂的患者亚组中,347 例中有 21 例(6.1%)发生术后出血。抗凝剂的使用是术后出血的显著预测因素(p<0.001)。
尽管自 2018 年以来限制了血栓预防治疗的应用,但 VTE 的发生率并未增加。这可能是由于快速通道方案鼓励快速活动和出院,从而导致血栓形成的风险增加。血栓预防治疗方案对术后出血率无显著影响。在 VTE 风险较低的代谢手术患者中,短期使用血栓预防治疗是安全的。